Table 2.

Subgroup analyses

VariableCategoryNo. patients with PFS2/PFS1 > 1.3No. patients (n = 193)P(PFS2/PFS1 > 1.3)95% CIFisher test for difference in proportions
Level of evidence1102737%19%–58%
2184144%28%–60%
3219522%14%–32%
4143047%28%–66%P = 0.15
RMH scoreRMH 0267933%23%–44%
RMH 1257932%22%–43%
RMH 292931%15%–51%
RMH 322100%16%–100%P = 0.67
Tumor typeMelanoma030%0%–71%
Breast133636%21%–54%
Head and neck81553%27%–79%
Thyroid and other endocrine glands020%0%–84%
Ill-defined primary tumor050%0%–52%
Digestive174538%24%–53%
Gynecological, female42417%5%–37%
Lung93228%14%–47%
Urological102842%19%–65%
Mesothelioma and soft tissue2367%9%–99%P = 0.73
Therapy classALK2633%4%–78%
AR2540%5%–85%
Cell cycle1520%1%–72%
DNA damage020%0%–84%
EGFR21217%2%–48%
ERBB2172665%44%–83%
FGFR72429%13%–51%
IDH1250%1%–99%
IGF1R11100%3%–100%
KIT11100%3%–100%
MAPK21217%2%–48%
MDM2020%0%–84%
MET31127%6%–61%
NOTCH62524%9%–45%
PI3K–AKT–mTOR185931%19%–44%P = 0.72
Year of inclusion2011030%0%–71%
2012154931%18%–45%
2013113829%15%–46%
2014215936%24%–49%
2015164436%22%–52%P = 0.95